ArticleThe Journal of infectious diseases2022
Older Adults Mount Less Durable Humoral Responses to Two Doses of COVID-19 mRNA Vaccine but Strong Initial Responses to a Third Dose.
Article in The Journal of infectious diseases, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 1 synthesis or guideline pooled it, 44 citations in OpenAlex.
- Efficacy, immunogenicity and safety of COVID-19 vaccines in older adults: a systematic review and meta-analysis.Frontiers in immunology · 2022Pooled it
- Safety, immunogenicity, and long COVID outcomes following inactivated COVID-19 vaccine boosters in elderly Chinese: a prospective cohort study.Frontiers in immunology · 2026Trial
- Modeling the kinetics of the neutralizing antibody response against SARS-CoV-2 variants after several administrations of Bnt162b2.PLoS computational biology · 2023Trial
- Comparative immunogenicity of mRNA-1273 and BNT162b2 SARS-CoV-2 bivalent booster vaccines in US nursing home residents.Human vaccines & immunotherapeutics · 2026Article
- Age-related differences in mRNA vaccine immunogenicity and adjuvancy.Immunology and cell biology · 2026Article
- Safety and antibody responses to inactivated COVID-19 vaccines among elderly patients with COPD: a prospective cohort study.Frontiers in immunology · 2026Article
- Neutralising antibody responses to emerging SARS-CoV-2 omicron sub-variants are enhanced in persons with hybrid immunity.Clinical & translational immunology · 2026Article
- Article
- Durability of antibody titers and associated factors after the booster dose of COVID-19 mRNA vaccination in Japanese SARS-CoV-2 infection-naive residents in geriatric intermediate care facilities.Geriatrics & gerontology international · 2025Article
- Review
- SARS-CoV-2 booster vaccine dose significantly extends humoral immune response half-life beyond the primary series.Scientific reports · 2024Article
- Impact of ageing on homologous and human-coronavirus-reactive antibodies after SARS-CoV-2 vaccination or infection.NPJ vaccines · 2024Article
- Antibody and transcription landscape in peripheral blood mononuclear cells of elderly adults over 70 years of age with third dose of COVID-19 BBIBP-CorV and ZF2001 booster vaccine.Immunity & ageing : I & A · 2024Article
- [Effect of previous exposure to COVID-19, occurrence of spikes, and type of vaccine on the humoral immune response of institutionalized older adults].Cadernos de saude publica · 2024Article
- Atypical B cells and impaired SARS-CoV-2 neutralization following heterologous vaccination in the elderly.Cell reports · 2023Article
- Cross-sectional Characterization of SARS-CoV-2 Antibody Levels and Decay Rates Following Infection of Unvaccinated Elderly Individuals.Open forum infectious diseases · 2023Article
- Decentralized study of COVID Vaccine Antibody Response (STOPCoV): Results of a participant satisfaction survey.PLOS digital health · 2023Article
- Challenges in the Vaccination of the Elderly and Strategies for Improvement.Pathophysiology : the official journal of the International Society for Pathophysiology · 2023Review
- COVID-19 vaccine antibody responses in community-dwelling adults to 48 weeks post primary vaccine series.iScience · 2023Article
- Impact of Age and Severe Acute Respiratory Syndrome Coronavirus 2 Breakthrough Infection on Humoral Immune Responses After Three Doses of Coronavirus Disease 2019 mRNA Vaccine.Open forum infectious diseases · 2023Article
Corrections and comments
- Commented on by
- Update of
Authors and funding
30 authors at 5 institutions in 1 country.
Funding
Abstract
backgroundThird coronavirus disease 2019 (COVID-19) vaccine doses are broadly recommended, but immunogenicity data remain limited, particularly in older adults.
methodsWe measured circulating antibodies against the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein receptor-binding domain, ACE2 displacement, and virus neutralization against ancestral and omicron (BA.1) strains from prevaccine up to 1 month following the third dose, in 151 adults aged 24-98 years who received COVID-19 mRNA vaccines.
resultsFollowing 2 vaccine doses, humoral immunity was weaker, less functional, and less durable in older adults, where a higher number of chronic health conditions was a key correlate of weaker responses and poorer durability. One month after the third dose, antibody concentrations and function exceeded post-second-dose levels, and responses in older adults were comparable in magnitude to those in younger adults at this time. Humoral responses against omicron were universally weaker than against the ancestral strain after both the second and third doses. Nevertheless, after 3 doses, anti-omicron responses in older adults reached equivalence to those in younger adults. One month after 3 vaccine doses, the number of chronic health conditions, but not age, was the strongest consistent correlate of weaker humoral responses.
conclusionsResults underscore the immune benefits of third COVID-19 vaccine doses, particularly in older adults.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.